Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Reata Pharmaceuticals Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Reata Pharmaceuticals Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 30 Nov 2022 | Lorem |
| Reata’s Omaveloxolone Prompts Experts to Seek Longer-Term Data in Friedreich’s Ataxia with Likely FDA Approval on the Way | 10 Nov 2022 | William Newton |
| Pulmonary hypertension diagnosis changes spark debate on trial inclusion criteria for clinical trials; off-label drug use needs better definition | 29 May 2019 | Manasi Vaidya |
| Reata’s bardoxolone methyl in final stretch of pivotal CTD-PAH study with approximately 10% accrual left, source says | 24 May 2019 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer